Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STC-1020
- Development stage
- Preclinical
- Lead developer
- Brenus Pharma
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
STC-1020 is an investigational therapeutic cancer vaccine developed by Brenus Pharma, designed for the treatment of solid tumors. It is part of the company's proprietary Stimulated-Tumor-(ghost)-Cell (STC) platform, which aims to mimic patient tumor relapse conditions and educate the immune system to recognize and destroy tumor cells. The platform leverages allogeneic tumor cell lines processed to present a broad range of tumor antigens, thereby overcoming issues with low immunogenicity and antigenicity seen in many cancer vaccines. The goal is to induce a robust anti-tumor immune response capable of targeting diverse solid tumors[4]. As of September 2024, STC-1020 remains in preclinical development in France for solid tumors[1].
- Other names
- STC-1020STC1020STC 1020
02
Targets
TAA/TSA (Tumor-associated and tumor-specific antigens)
Beyond the preview
Go deeper on STC-1020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STC-1020.